The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical ...( DOYLESTOWN Pa. Oct. 30 /- The Qui...),Health

DOYLESTOWN, Pa., Oct. 30 /PRNewswire-FirstCall/ -- The Quigley Corporation (Nasdaq: QGLY), http://www.quigleyco.com today reported net sales from continuing operations of $6.4 million, for the third quarter ended September 30, 2008, compared to $9.1 million reported for the third quarter ended September 30, 2007. For the nine months ended September 30, 2008, net sales were $13.7 million compared to $17.5 million reported for the nine months ended September 30, 2007.

The third quarter and nine month periods of 2008 reflect a net sales decrease as a result of a slow start to the 2007/2008 cold season and changes to customers' buying habits. The 2008 periods' net sales were favorably offset by sales of the Kids-EEZE(R) Chest Relief product line, which was launched in August 2008 and a price increase which commenced in the third quarter of 2007. Kids-EEZE(R) Chest Relief, http://www.kids-eeze.com is a single-ingredient, allopathic expectorant with guaifenesin to help children, ages six and up, suffering from uncomfortable chest congestion. Kids-EEZE(R) Chest Relief provides an alternative to the many multi-symptom children's cold products that could potentially lead to overmedication. The Company has initiated an advertising and targeted couponing campaign to promote the COLD-EEZE(R) brand and brand extensions during the forthcoming cold season.

Income from continuing operations for the third quarter ended September 30, 2008 was $879,000, or $0.07 per share, compared to $1.4 million, or $0.11 per share for the third quarter of 2007. Loss from continuing operations for the nine months ended September 30, 2008, was $4.4 mill
'/>"/>